INSTITUTO DE INVESTIGACIÓN BIOMÉDICA DE SALAMANCA
Instituto
Dalhousie University
Halifax, CanadáPublicaciones en colaboración con investigadores/as de Dalhousie University (22)
2022
-
Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma
Blood, Vol. 140, Núm. 21, pp. 2248-2260
2020
-
As COVID-19 cases, deaths and fatality rates surge in Italy, underlying causes require investigation
Journal of Infection in Developing Countries, Vol. 14, Núm. 3, pp. 265-267
-
COVID-19 as a cardiovascular disease: the potential role of chronic endothelial dysfunction
Cardiovascular research, Vol. 116, Núm. 10, pp. e132-e133
-
Lymphopenic community acquired pneumonia as signature of severe COVID-19 infection
Journal of Infection
-
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial
The Lancet, Vol. 396, Núm. 10262, pp. 1563-1573
-
Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial
The Lancet Haematology, Vol. 7, Núm. 5, pp. e370-e380
-
Viral RNA load in plasma is associated with critical illness and a dysregulated host response in COVID-19
Critical Care, Vol. 24, Núm. 1
2019
2017
-
Genetic association study of exfoliation syndrome identifies a protective rare variant at LOXL1 and five new susceptibility loci
Nature Genetics, Vol. 49, Núm. 7, pp. 993-1004
-
Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial
The Lancet Oncology, Vol. 18, Núm. 2, pp. 241-250
2016
-
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): An open-label, randomised, phase 2 trial
The Lancet, Vol. 387, Núm. 10027, pp. 1551-1560
-
Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356
Autophagy
-
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)
Autophagy, Vol. 12, Núm. 1, pp. 1-222
-
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
The Lancet Oncology, Vol. 17, Núm. 8, pp. e328-e346
2015
-
American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma
Biology of Blood and Marrow Transplantation, Vol. 21, Núm. 12, pp. 2039-2051
-
Designing a broad-spectrum integrative approach for cancer prevention and treatment
Seminars in Cancer Biology, Vol. 35, pp. S276-S304
-
Elotuzumab therapy for relapsed or refractory multiple myeloma
New England Journal of Medicine, Vol. 373, Núm. 7, pp. 621-631
2013
-
Drug uptake, lipid rafts, and vesicle trafficking modulate resistance to an anticancer lysophosphatidylcholine analogue in yeast
Journal of Biological Chemistry, Vol. 288, Núm. 12, pp. 8405-8418
-
Hace1 controls ROS generation of vertebrate Rac1-dependent NADPH oxidase complexes
Nature Communications, Vol. 4
2012
-
Guidelines for the use and interpretation of assays for monitoring autophagy
Autophagy, Vol. 8, Núm. 4, pp. 445-544